Respiratory Tract Infection Treatment Market By Disease (Upper Respiratory Tract Infection, Lower Respiratory Tract Infection), By Drug Class (Antibiotics, Antiviral, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppresant, Nasal Decongestant) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

This report on global respiratory tract infection treatment market studies various diseases and drug class. Rising prevalence of respiratory illness as per World Health Organization in 2015 three million deaths were recorded due to COPD, constantly changing climate, rising air pollution and increasing inclination to maintain personal hygiene are the drivers for the respiratory tract infection treatment market. 

The limiting factors related to this market are the rising incidence of antibiotic resistance and adverse events relating to the consumption of NSAIDs will hinder the growth of respiratory infection treatment market. Technological advancement in the pharmacokinetics and drug screening for adverse events will result into deep market penetration. The increasing consumption of cheap generic medicines will hinder the branded drugs market. The drugs in the pipeline are Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead) and AZD7594, PT010 (AstraZeneca) etc.

For the purpose of this study, the various diseases studied include upper respiratory tract infection, lower respiratory tract infection and others. Drug class studied for the purpose of this research include antibiotics, non-steroidal anti-inflammatory drug (NSAIDS), cough suppressant, nose decongestant and others, upper respiratory tract infection is further segmented as (common cold, sinusitis, epiglottitis and laryngitis) lower respiratory tract infection are further segmented as (flu, bronchitis, pneumonia, asthma, COPD and respiratory syncytial virus). The geographic segmentation of the global respiratory tract infection treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Rest of LATAM
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa
  •  

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year. This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global respiratory tract infection treatment market. 

Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global respiratory tract infection treatment market. The key players profiled in this report are Abbott Laboratories, Abbvie Inc, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Novartis AG and others.

For the purpose of this study, the global respiratory tract infection treatment market is categorized into:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

North America was observed as the largest market for respiratory tract infection treatment in the base year 2016. According to Centers for Disease Control and Prevention (CDC) American adults have 2 to 3 colds per year with underlying symptoms such as runny nose, sore throat, coughing, sneezing, headaches and body aches. The growth is attributed mainly due to large population suffering from respiratory complications and inclination to maintain personal hygiene along with favorable reimbursement scenario. 

Europe is expected to be the second largest market due to cool and damp weather favoring respiratory disease and regulatory approval for respiratory tract infection treatment products. Growth of Asia Pacific for respiratory tract infection treatment market is attributed by factors like rising prevalence of respiratory illness among huge population base, competitive market due to manufactures involved in respiratory tract infection treatment products, and impact of monsoon weather in the South Asian countries. However, factors such as developing health infrastructure, increasing disease awareness and increasing demand for respiratory tract infection treatment products are going to fuel the growth of respiratory tract infection treatment market in Latin America and Middle East and Africa region in the near future.